目的:本研究旨在探讨帕罗西汀在治疗药物监测中血药浓度的相关影响因素,并建立我院帕罗西汀血药浓度参考区间,为临床安全、合理地使用帕罗西汀提供参考。方法:收集我院2021年1月至2023年12月服用帕罗西汀治疗抑郁症达稳态血药浓度患者监测数据共272例统计学资料,考察性别、年龄、日剂量、民族、联合用药对帕罗西汀稳态谷浓度的影响,并建立帕罗西汀血药浓度参考区间,结合病例情况分析影响帕罗西汀稳态血药浓度的影响因素。结果:研究初步确定我院患者使用帕罗西汀治疗抑郁症时不同性别稳态血药浓度的参考区间。在相同日给药剂量下不同年龄、不同联合用药、不同民族患者帕罗西汀血药浓度的差异无统计学意义(P > 0.05)。但在30 mg/d和40 mg/d的剂量下,男性与女性的血药浓度存在显著差异(P Objective: The aim of this study is to explore the relevant influencing factors of paroxetine blood concentration in therapeutic drug monitoring, and to establish the reference interval of paroxetine blood concentration in our hospital, so as to provide reference for the safe and reasonable use of paroxetine in clinical practice. Methods: A total of 272 cases of statistical data were collected from January 2021 to December 2023 from our hospital to take paroxetine to treat depression up to steady-state blood concentration patients monitoring data, to investigate the influence of gender, age, daily dose, ethnicity, and combination of drugs on the steady-state trough concentration of paroxetine, and to establish the reference interval of paroxetine blood concentration, combined with the case situation to analyse the impact of the influence of the steady-state blood concentration of paroxetine factors. Results: The study preliminarily determined the reference intervals for steady state blood concentrations of different genders in the treatment of depression with paroxetine in our patients. The differences in
目的研究帕拉米韦三水合物注射液在健康志愿者的药代动力学试验。采用液相串联质谱联用法(LC-MS/MS)对待测生物样品进行分析,测定主要成分帕拉米韦的血药浓度,估算其主要药代动力学参数,了解帕拉米韦三水合物注射液在健康人体内的吸收,为制定帕拉米韦三水合物注射液的临床试验方案提供试验依据,同时也为临床用药的给药剂量提供依据。方法采用Agilent Eclipse Plus C18色谱柱(4.6mm×100mm,5μm),甲醇∶水(0.1%甲酸、0.06mmol·L^-1甲酸铵)70∶30(V/V)为流动相等度洗脱,流速为0.5mL·min^-1,柱温35℃。采用多重反应监测(MRM)帕拉米韦(m/z329.0→270.0)和内标氘代帕拉米韦(m/z332.1→273.1)的测定。结果帕拉米韦的线性范围为5~10000ng·mL^-1。其相关系数r2=0.9921,定量下限为5ng·mL^-1,批内和批间的RSD分别为3.61%和4.08%以内,准确度在95.75%~106.42%之间。结论该方法灵敏、快速、简单、准确,可用于帕拉米韦的临床血药浓度监测和药代动力学研究。
目的:探讨并优化帕罗西汀血药浓度监测中的样品前处理方法,旨在通过引入瓶内处理技术和自动化样品前处理系统,实现快速、高效的前处理流程,提高监测效率与准确性。方法:综述了两种关键的优化策略:一是采用特制瓶内置过滤膜的瓶内处理技术,直接在单一瓶内完成样品分离与杂质去除;二是引入自动化样品前处理系统,如固相萃取自动化平台和在线样品处理系统,通过预设程序自动化完成样品提取、净化、浓缩等步骤。结果:这些优化方法显著缩短了样品前处理时间,平均处理时间从数小时缩短至数分钟至半小时内,提高了监测效率。同时,确保了分析结果的准确性和一致性,减少了人为操作带来的误差。此外,自动化系统的应用降低了人力成本,满足了高通量监测的需求。结论:通过引入瓶内处理技术和自动化样品前处理系统,帕罗西汀血药浓度监测的样品前处理过程实现了快速与高效。这些优化策略不仅提升了监测效率,还保证了分析结果的准确性,为临床用药指导和个体化治疗提供了有力支持。Objective: To explore and optimize the sample pre-treatment method in Paroxetine blood drug concentration monitoring. It aims to achieve a fast and efficient pre-processing process by introducing in-bottle treatment technology and automation sample processing systems to improve monitoring efficiency and accuracy. Methods: Two key optimization strategies are summarized: First, the in-bottle processing technology of the special bottle built-in filter film is used to complete the sample separation and impurity removal directly in a single bottle;And second, the automated sample pre-treatment systems are introduced, such as an automated platform for solid-phase extraction and an online sample processing system, to automatically complete the sample extraction, purification, concentration and other steps through the pre-set program. Result: These optimizati
